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Abstract Plasma levels o f a n t i t h r o m b i n I I I , «2-macrog lobul in and inter -a-
t ryps in i n h i b i t o r , as wel l as those o f various c l o t t ing , complement and other 
plasma factors, were s igni f i cant ly decreased in 18 patients suf fer ing f r o m 
hyperdynamic septic shock. A s imi lar statistically signif icant reduct ion o f the 
concentrat ions o f several plasma factors ( p r o t h r o m b i n and a n t i t h r o m b i n I I I , 
p lasminogen and «2-plasmin i n h i b i t o r , complement factor C3 and c l o t t ing factor 
X I I I ) was observed in exper imental endotoxaemia. I n this model the reduct ion in 
the plasma levels o f these factors was considerably d imin ished by the intravenous 
in ject ion o f a granulocyt ic elastase-cathepsin G i n h i b i t o r o f lower molecular 
weight f r o m soybeans. The results o f bo th studies indicate that consumpt ion o f 
plasma factors in the course o f Gram-negat ive sepsis proceeds not on ly via the 
classical routes (by ac t i va t ion o f the c lo t t ing , f i b r ino l y t i c and complement 
cascades by system-specific proteinases such as thrombok inase or the plasminogen 
act ivator ) bu t also to an appreciable degree by unspecific degradat ion o f plasma 
factors by neutra l proteinases such as elastase and cathepsin G . The endotox in-
induced release o f b o t h sorts o f proteinases, the system-specific ones and the 
unspecif ic lysosomal proteinases f r o m leucocytes and other cells, is l ike ly to be 
main ly responsible for the c onsumpt i on o f a n t i t h r o m b i n I I I and c*2-macroglobulin 
via complex f o r m a t i o n ( f o l l owed by e l im ina t i on o f the complexes) and the 
increased turnover o f the in t e r -a - t r yps in i nh ib i t o r as observed in the c l in ica l study. 
The therapeutic use o f an exogenous elastase-cathepsin G i n h i b i t o r in the 
exper imental mode l was s t imula ted by the observat ion that h u m a n mucous 
secretions conta in an acid-stable i n h i b i t o r o f the neutra l granulocyt ic proteinases, 
called H U S I - I o r ant i leucoprote inase. Th is i nh ib i t o r protects mucous membranes 
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and soluble proteins against proteo ly t ic attack by leucocytic proteinases released 
in the course o f a local i n f l ammato ry response. P re l iminary results indicate that 
HUS1- I , wh i ch is produced by the epithel ia l cells o f mucous membranes, does not 
belong to any k n o w n st ructura l type o f acid-stable proteinase i nh ib i t o r . The 
search for other candidates suitable for medicat ion in humans led to the discovery 
o f a potent elastase-cathepsin G inh ib i t o r , called eg l in, in the leech Hirudo 
medicinalis. This acid-stable i n h i b i t o r w i t h a molecular weight close to 8100 has 
an unusual s t ructura l proper ty in that the structure o f the molecule is not 
stabil ized by any d isulphide bridge. 
The course o f a disease l ike septicaemia or septic shock is o f ten complicated 
by severe pathobiochemical processes in the c i rcu la t ion . These are, for 
example, disseminated intravascular coagulat ion (D IC ) caused by act ivat ion 
o f the c lo t t ing and f ibr ino ly t i c cascades, and anaphylactic responses induced 
by act ivat ion o f the complement system (Hami l t on et al 1978, Müller-
Berghaus et al 1976, Garner et al 1974, McCabe 1973). These act ivat ion 
reactions may be triggered by endotoxins — that is, l ipopolysaccharides f r o m 
Gram-negative bacteria (Jeljaszewicz & Waldström 1978, Urbaschek et al 
1975). Endotox ins can damage biological membranes and thus induce the 
release o f constituents, so-called mediators o f i n f l ammat i on , inc lud ing 
lysosomal enzymes, f r om various body cells (Weissmann 1974, Urbaschek et al 
1975, M y r v o l d 1976, Mova t 1979). These enzymes normal ly exhibit their 
physiological func t ion , namely degrading phagocytosed mater ia l , inside the 
cell (K lebanof f & Clark 1978). I f released into the c i rcu la t ion , however, they 
may enhance the in f l ammatory response by several routes. 
System-specific proteinases such as the plasminogen activator and 
thrombokinase activate the b lood systems (see Fig. 1) by proenzyme — 
enzyme conversion — that is, by specific proteolyt ic cleavages. These 
enzymes are responsible, therefore, for the 'classical' or specific consumpt ion 
o f factors o f these systems, inc luding the inhib i tors o f c lo t t ing ( A T I I I ) , 
ka l l ikre in ( C I I N A ) , f ibrinolysis (azPI) and complement ( C I I N A ) factors (cf. 
Fig. 2 and Table 1). E l im ina t i on o f both the proteinases and inhib i tors o f the 
b lood systems also proceeds specifically by the f o rmat ion o f 
enzyme- inh ib i t o r complexes that are phagocytosed by cells o f the 
ret iculoendothel ial system (RES) (Ohlsson 1974, Ohlsson & Laure l l 1976, 
Ohlsson 1978). 
More recently it became evident f r om studies in vitro and in vivo that 
endotoxin- induced consumpt ion o f plasma proteins might also be due to a 
significant degree to unspecific degradation by leucocytic proteinases, 
especially an elastase (cf. Figs. 1 and 2) (Schmidt et al 1974, Haschen 1975, 
Egbr ing et al 1977, Egbr ing & Havemann 1978, Schiessler et al 1978a, Aasen 
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Proteinases released from cells can cause: 
Activation 
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S p e c i f i c 
Degradation 
I 
Blood system factors, other 
blood proteins, proteinase 
inhibitors 
I 
U n s p e c i f i c 
c o n s u m p t i o n 
F I G . 1. Effects of proteinases released from blood and tissue cells during inflammation on blood 
systems and plasma factors. 
& Ohlsson 1978). I n such unspecific consumpt ion reactions — wh ich , i n 
contrast to the specific consumpt ion , are not l imited to the factors o f the 
b l o o d systems (cf. F ig . 1) — the biological act iv i ty o f the plasma proteins is 
irreversibly destroyed by proteo lyt ic degradation. The l iberated leucocytic 
proteinases are e l iminated, however, i n a specific manner by the f o rmat i on o f 
complexes w i th proteinase inh ib i to rs such as c ^ M , ct\A and cnAC (see Fig . 2 
and Table 2) and the phagocytosis o f the complexes by the RES (Ohlsson & 
Laure l l 1976, Debanne et al 1976). 
Consumption reactions 
Specific activation Unspecific degradation 
e.g. thrombokinase, 
plasminogen activator 
e.g. PMN elastase, 







e.g. AT II 
Plasma proteinase inhibitors 
1 cx2P\, C1 INa e.g. αλ A, a i x AC, a 2M 
1 
ion (RES) 
F I G . 2. Consumption of plasma factors during inflammation. System-specific proteinases such as 
thrombokinase activate the blood system factors which are inhibited thereafter by complex 
formation with antithrombin I I I (AT I I I ) , a2-plasmin inhibitor (a2PI) and CI inactivator (CI 
INA) , respectively. Proteinases liberated from blood and tissue cells like granulocytic (PMN) 
elastase can degrade plasma factors unspecifically before being inhibited by complex formation 
with cYj-antitrypsin (αϊA) , aj-antichymotrypsin (ajAC) and c*2-macroglobulin (c*2M), respecti­
vely. The enzyme-inhibitor complexes are eliminated from the circulation by cells of the reticu­
loendothelial system (RES). 
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TABLE 1 
Plasma proteinase inhibitors of blood system factors (cf. Fig. 1). Theoretically highest possible 
plasma concentrations of these factors are given in parentheses (in /xmol/1). For literature 
references see Heimburger 1975, Harpel & Rosenberg 1975, Collen et al 1979 
Inhibitor Abbreviation Concentration 
frmol/i) 
Factors primarily inhibited in vivo 
Antithrombin I I I AT I I I 4.0 Thrombin ( l ) a , factor Xa a 
+ heparin + plasmin 6 , + kal l ikrein 6 
(*2-Plasmin inhibitor c*2PI 0.9 Plasmin/ogen (2) 
C I inactivator C I INA 2.4 CTs, CTr ( <1 ) , 
kallikrein (~ 1) 
aReacting with A T I I I slowly without heparin but rapidly with heparin. 
b Only in the presence of heparin after consumption of c^PI or C I INA (Highsmith & Rosenberg 
1974, Venneröd et al 1976), respectively. 
The factual basis o f this concept is that the early phase o f experimental 
septic shock is characterized by the release o f cell constituents inc lud ing 
proteinases f r o m leucocytes, platelets, macrophages, mast cells and 
endothelial cells o f the vessel walls, especially those o f the lung capillaries 
(Weissmann 1974, Urbaschek et al 1975, M y r v o l d 1976, Starkey 1977, V a n e & 
Ferreira 1978, Aasen & Ohlsson 1978, Mova t 1979). Because o f the presence 
TABLE 2 
Plasma inhibitors directed primarily against lysosomal proteinases of various body cells. For 
literature references see Heimburger 1975, Starkey & Barrett 1977 teM), Travis et al 1978 (a\A, 
a iAC ) , Ohlsson 1978 (crjA, a j A Q , Woolley et al 1976 (jojCI) 
inhibitor Abbreviation Concentration Strong inhibition of (in vitro, 
(\kmol/l) probably also in vivo): 
o!2-Macroglobulin cx2M 3.6 Neutral and acidic proteinases3 
(complex elimination ty, ~ 10 min) 
oc\-Antitrypsin (α-1-Pro­
tease inhibitor) 
αιΑ 52 Neutral proteinases from leuco­
cytes6, pancreas and other tissues 
α ι - Antichymotrypsin a jAC 6.4 Chymotrypsin, cathepsin G 
β ι-Collagenase inhibitor ßiCl ~0 .4 C True collagenases (metallo enzymes) 
Inter-a-trypsin 
inhibi tor d 
I T I 2.8 Trypsin, chymotrypsin, acrosin 
ae.g. granulocyte neutral proteinase (formerly collagenase, Ohlsson 1980), cathepsin G, elastases, 
collagenases, trypsin, chymotrypsin, plasma kallikrein; cathepsin Β and D, etc. 
be.g. elastase and neutral proteinase (cf. a ) . 
cEstimated value according to Woolley et al 1976. 
d The biological antagonists are not yet known, see text. 
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o f potent proteinase inh ib i t o rs , however, direct measurement o f proteinase 
activities i n plasma or serum is not feasible. We have focused our ef forts, 
therefore, on indirect indicat ions such as the consumpt ion o f plasma 
proteinase inh ib i t o r s , the turnover o f selected plasma proteins, and the 
concentrations o f plasma factors expected to be either signif icantly elevated or 
d iminished dur ing septicaemia or septic shock. I n another approach we tested 
the therapeutic effect o f an exogenous inh ib i to r o f neutral leucocytic 
proteinases on the plasma levels o f various plasma proteins inc luding 
proteinase inh ib i to rs dur ing experimental endotoxaemia. The results 
obtained st imulated us to cont inue the search for potent inh ib i tors o f 
leucocytic proteinases as possible therapeutic agents preventing unspecific 
consumpt ion o f plasma factors dur ing septicaemia or septic shock. 
HYPERDYNAMIC SEPTIC SHOCK: A CONTROLLED C L I N I C A L TR IAL 
Criteria and methods 
Criteria, The patients suf fer ing f r om hyperdynamic septic shock (n= 18, 
age 17-70 years) had to f u l f i l a l l o f the f o l l ow ing cr i ter ia: body temperature 
>38.5 °C, leucocytes > 1 5 000 or < 5 000/mm 3 , platelets < 1 3 0 000/mm 3 , 
positive b lood culture (twice) , positive evidence o f endotox in in serum (at least 
twice), cardiac index > 6 1/min/m 2 body surface, to ta l peripheral resistance o f 
the vessel system < 6 0 0 dyn χ s/cm 5 , mean arterial b lood pressure 80 -90 
m m H g (10.7-12.0 kPa) , a l l c l in ical signs o f septic shock (Wi t te 1979). 
Therapy. The f o l l ow ing therapeutic measures were taken: surgical 
cleansing o f the septic focus, vo lume subst i tut ion w i th human a lbumin under 
contro l o f the pu lmonary capi l lary wedge pressure, cont inuous low dose 
heparin therapy (200-400 U/h) , the infusion o f 100-400 ^g/min dopamine to 
mainta in an urine ou tput o f at least 80 -100 m l / h , adminis t ra t ion o f 30 mg/kg 
body weight o f methylprednisolone every 6 h up to 48 h (to prevent acute 
respiratory distress syndrome), medicat ion w i th antibiot ics according to the 
sensitivity patterns o f the microorganisms, and parenteral nu t r i t i on as well as 
mechanical vent i latory assistance (Wi t te 1979). 
Methods. A l l parameters were fo l lowed up for four days after the patients 
ful f i l l ed al l the above cr i ter ia o f hyperdynamic septic shock. Haemodynamic 
measurements were made and b lood samples were taken at the beginning and 
6, 12, 18, 24, 36, 48, 72 and 96 h thereafter. Further experimental details are 
given in the academic thesis o f J . Wi t t e (1979) and w i l l be published 
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elsewhere. O f the various haematological , haemodynamic and biochemical 
data fo l lowed up dur ing the observation per iod, only those relevant to the 
topic o f this paper are reported here. 
Activation of blood systems and concentration pattern of plasma factors 
Acute-phase proteins. In f l ammatory processes in the organism are 
accompanied by increased serum or plasma levels o f the acute-phase proteins. 
Indeed, the serum concentrations o f C-reactive protein and ai-glycoprotein 
were signif icantly elevated dur ing the septic shock phase (Table 3). Probably 
because o f compet i t ion w i t h consumpt ion (cf. below), the mean plasma level 
o f fibrinogen, another acute-phase pro te in , was i n the upper part o f the 
standard range rather than above i t (Table 3). The high p roduc t i on rate o f 
these acute-phase proteins strongly indicates that the synthetic capacity o f the 
organism, especially o f the l iver, for the various plasma proteins was not yet 
restricted dur ing the hyperdynamic septic shock phase. 
Clotting and fibrinolysis. Permanent act ivat ion o f the c lo t t ing cascade by 
system-specific proteinases throughout the observation per iod is indicated by 
the highly signi f icantly increased plasma concentrat ion o f fibrinopeptide A 
(Table 3), which is cleaved f r om f ibr inogen by the specific act ion o f t h r o m b i n 
(Gaffney 1977, Schramm et al 1980). S imi lar ly , act ivat ion o f plasmin and 
thus o f f ibrinolysis is responsible for the elevated plasma levels o f fibrin(ogen) 
split products (FSP, cf. Table 3) (Skansberg et al 1974). I n this case, however, 
a tendency to normal i za t ion was clearly visible towards the end o f the 
observation per iod. 
Complement. Complement act ivat ion dur ing the shock phase proceeded 
pr imar i l y via the alternative pathway. This may be deduced f r om the clearly 
lower plasma level o f complement factor C3 than o f C4 (Table 3). This result 
is in agreement w i th our present knowledge o f the act ivat ion mechanism o f 
the complement cascade in endotoxaemia (Johnson et al 1976, Spragg & 
Austen 1977, Nicholson et al 1978, T u r k & Wi l l oughby 1978, Aasen et al 
1980). O f special interest in this respect is the observation that the 
granulocyt ic elastase is capable o f cleaving C3 in such a way that direct 
act ivat ion o f the complement cascade via the alternative route could indeed 
result (Johnson et al 1976, Aasen et al 1980). On the other hand, there is 
g rowing evidence that endotoxins can trigger the release o f elastase f r om 
granulocytes (Aasen & Ohlsson 1978, Egbr ing et al 1977). 
Liberated elastase could also be responsible, at least par t ly , for the highly 
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TABLE 3 
Plasma or serum levels of various biochemical parameters in septic shock. Standard values 
(norm) are given both as mean value and range (in parentheses). The values given at the 
beginning of the shock phase (0 h) and after 96 h are mean values x{n = 18) with the 
corresponding standard deviations ( ± SEM). Ρ, statistical significance (Student r-test) 
Measured parameter Norm Oh 96 h Ρ 
C-reactive protein (mg/dl) <1.2 13.5 ± 1.3 10.4 + 1.6 <0 .001 a 
ai-Glycoprotein (mg/dl) 90(55-140) 139.3 ± 7.9 b 132.9 ± 15.2 b <0.001 a 
Fibrinogen (mg/dl) 180-380 359.7 ± 23.4 293.5 ± 17.4 >0.05 a 
Fibrinopeptide A (ng/ml) <3.0 13.1 ± 2.7 18.1 ± 4.5 <0.001 a 
Factor X I I I (mg/dl) - 2 46.1 ± 4.9 b 52.9 ± 4.8 b <0.001 a 
FSP'c fog/ml) < 10.0 21.4 ± 4.1 10.7 ± 1.7 <0.05 d 
Complement C3 (mg/dl) 82(55-120) 70.1 ± 4.3 b 65.3 ± 6.7 b < 0 . 0 1 a 
Complement C4 (mg/dl) 30(20-50) 82.2 ± 11.2b 74.5 ± 11.2 b >0.05 a 
a For both 0 and 96 h. bExpressed as °7o o f the norm. cFibrin(ogen) split products. d For the 0 h 
value only. 
signif icant (P <0 .001) consumpt ion o f factor XIII (45—55% reduct ion in the 
plasma concentrat ion) th roughout the shock phase. This view is supported by 
the results o f an imal studies showing that therapeutic admin is t ra t ion o f an 
elastase-cathepsin G inh ib i t o r in experimental septicaemia can prevent factor 
X I I I consumpt ion to a large degree (Schiessler et al 1978a). 
Plasma proteinase inhibitors 
Marked consumpt ion or turnover o f plasma proteinase inhib i tors dur ing 
the septic shock phase reflects extensive act ivat ion o f the b lood systems as well 
as the l iberat ion o f considerable amounts o f proteinases f r om various body 
cells, especially the granulocytes, in our patients. 
Antithrombin I I I ( A T I I I ) is the most impor tant inh ib i t o r for mainta in ing 
the homeostasis o f the c lo t t ing system. To fu l f i l its physiological or 
pathophysiological func t i on , namely regulat ion o f the act iv i ty o f factor Xa 
and th r omb in to prevent thrombosis , A T I I I levels w i th in or close to the 
standard range are necessary; the risk o f thrombosis increases considerably 
w i th decreasing A T I I I plasma levels (Harpe l & Rosenberg 1975, Seegers 1978, 
Collen et al 1979). 
In our patients the A T I I I concentrat ion was already reduced to 5 0 % o f the 
standard mean value at the beginning o f the observation period (Fig. 3). This 
indicates major consumpt ion o f A T I I I by the f o rmat i on o f complexes w i th 
the activated c lot t ing factors. W i t h the heparin medicat ion necessary to 
prevent thrombosis or disseminated intravascular coagulat ion, the 
consumption o f A T I I I is even further intensif ied, since the hepar in-AT I I I 
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F I G . 3. Plasma levels of antithrombin I I I during hyperdynamic septic shock. The curves show 
mean values χ of all patients (n - 18, ), of the patients surviving the shock phase (n = 15, 
), and of patients who died close to the end of the observation period (n = 3, ); 
standard deviations ( ± SEM) of the mean values χ are indicated for each test point. Ordinate, 
the percentage related to the standard level (estimated with pooled plasma from normal 
individuals). Abscissa, observation period. Antithrombin I I I concentration was estimated by 
LaurelPs electroimmunoassay (rocket technique). For further details see text. 
complex also reacts w i t h other proteinases such as factor V i l a , I X a , X I a , X l l a 
and plasma ka l l i k re in (Col len et al 1979). Most remarkably , i n the patients 
surviv ing the shock phase ( f l =15 ) the A T I I I level increased cont inuously 
whereas it decreased dramatical ly i n those patients who died (n = 3) dur ing the 
shock phase (close to the end o f the observation per iod, cf. F ig . 3). 
ai-Macroglobulin. The permanently low level o f a2-macroglobul in (aiM) 
throughout the septic shock phase is especially s t r ik ing (Fig. 4). Obv ious ly , 
considerable amounts o f neutral and acidic proteinases (cf. Table 2) are 
cont inuously l iberated in to the c i rculat ion f r om the various body cells, leading 
to major consumpt ion o f this most impor tan t proteinase-el iminating vehicle 
(Col len et al 1979, Ohlsson 1978, Starkey & Barrett 1977, Ohlsson & Laure l l 
1976, Harpe l & Rosenberg 1975). 
Considering the proteolyt ic potent ia l which might be l iberated by endotox in 
s t imulat ion f r om polymorphonuclear ( P M N ) leucocytes alone, for example 
approximate ly 1 g o f bo th elastase and neutral proteinase ( f o rmer ly 
collagenase) and 0.3 g o f cathepsin G per day (Laure l l 1975, Ohlsson 1980), 
the protective role o f aiM against unspecific proteolysis cannot be suf f ic ient ly 
emphasized. I n fact, onM seems to be chiefly responsible for the i n h i b i t i o n 
(cathepsin G, neutral proteinase) and e l iminat ion ( inc luding elastase, wh i ch is 
p r imar i l y inhib i ted by αι-antitrypsin but probably transferred to a2M for this 
purpose) o f these granulocyt ic proteinases (Ohlsson 1978, Ohlsson & Laure l l 
1976). 
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F I G . 4. Plasma levels of a2-macroglobuiin (c^M) and serum levels of native inter-a-trypsin inhi­
bitor (ITI160000) and acid-stable ITIiöoooo-derived ITI30000 during hyperdynamic septic shock. 
The curves represent mean values χ o f Λ = 18 teM) or η = 10 (ITI) patients; standard deviations 
( ± SEM) of the mean values χ are indicated for each test point. Ordinate, the percentage of the 
standard level o f c*2M (estimated with pooled plasma from normal individuals) and the trypsin 
inhibitory activity o f I T I (substrate BzArgNHNp) per ml serum. Abscissa, observation period. 
C Q M was estimated by Mancini's radial immunodiffusion technique. I T I 1 6 0 000 and I T I 3 0 000 were 
determined according to Hochstrasser et al (1977a) by measuring the trypsin inhibitory activity of 
the supernatant of an acidified serum sample (ITI30000) and of the trypsin-treated precipitate 
after trypsin denaturation (ITIieoooo). 
Inter-a-trypsin inhibitor. Recent observations indicate increased turnover 
o f the inter-a- tryps in inh ib i t o r ( I T I ) dur ing septicaemia (Hochstrasser et al 
1977b). Indeed, the level o f native I T I ( I T I 1 6 0 0 0 0 ) was signif icantly reduced 
throughout the observation per iod whereas the concentrat ion o f the I T I -
derived acid-stable i nh ib i t o r ( I T I 3 0 0 0 0 ) was signif icantly increased (Fig. 4). 
Studies in vitro showed that o f the various proteinases tested, granulocyt ic 
elastase (and cathepsin G ; K. Hochstrasser, personal communicat ion ) are 
capable o f l iberat ing I T I 3 0 0 0 0 most rap id ly f r o m ITI160000 (D ied et al 1979). 
This might mean that granulocyt ic proteinases are also responsible for the 
high turnover o f I T I i n septicaemia or septic shock. 
Though the bio logical funct ion o f ITI160000 or ITI30000 is not yet clear, 
ident i f icat ion o f the inh ib i t o r y active domain(s) as Kuni t z - or aprot in in-type 
inhib i tors is remarkable (Wächter & Hochstrasser 1979). 
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Conclusions and outlook 
The fo l l ow ing aspects o f the cl inical study should be especially emphasized. 
(i) The plasma or serum levels o f the measured parameters had already 
reached pathological values when the first c l inical signs o f septic shock were 
established. This means that the search for other biochemical parameters 
suitable for ident i fy ing the onset o f septicaemia or septic shock has to be 
cont inued. 
(ii) Consumpt ion o f plasma factors i n hyperdynamic septic shock and 
probably also in Gram-negative septicaemia is due to the proteolyt ic attack o f 
bo th system-specific and unspecific proteinases l iberated f r om leucocytes and 
other body cells. The large consumpt ion o f the protective potent ia l o f the 
plasma inhib i tors by the f o rmat i on o f complexes w i th these proteinases, 
fo l lowed by rapid e l iminat ion o f the complexes, is especially s t r ik ing . 
( i i i ) The possibi l i ty o f reducing the consumpt ion o f plasma factors by 
administer ing suitable proteinase inh ib i tors should be envisaged. I n our 
op in ion such inhib i tors should p r imar i l y prevent the consumpt ion o f c ^ M , A T 
I I I and «2-plasmin inh ib i t o r (a2PI). App l i ca t i on at an early phase o f 
septicaemia seems to be most promis ing . Whereas a potent plasmin inh ib i t o r 
( apro t in in , the effective agent in the drugs Trasylcl®, Antagosan® or 
Iniprol®) is already available for medical use, in the other two cases on ly 
subst i tut ion w i th A T I I I (Schramm 1977) or aiM concentrates is possible at 
present. 
T H E A C I D - S T A B L E E L A S T A S E - C A T H E P S I N G I N H I B I T O R O F H U M A N M U C O U S 
S E C R E T I O N S 
Inhibitory properties 
Our search for inhib i tors suitable for therapeutic use in humans was 
st imulated by the f ind ing that the acid-stable t ryps in-chymotryps in inh ib i t o r 
f r om human seminal plasma (HUSI - I ) also has strong a f f in i ty for 
granulocyt ic elastase and cathepsin G (Schiessler et al 1976a). For the 
corresponding enzyme- inh ib i to r complexes, K\ values close to 1 χ 1 0 " 9 
moi/1 (human granulocyt ic elastase, bovine chymotryps in and trypsin) and 
5 x 10~ 8 mol/1 (human granulocyt ic cathepsin G) were f ound . 
Biochemical and structural features 
H U S I - I isolated in our laboratory f r o m human seminal plasma consists o f 
PROTEINASE INHIBITORS IN I N F L A M M A T I O N 361 
several mul t ip le forms having the same inh ib i to ry characteristics and similar 
molecular weights o f approximate ly 11 000 (Schiessler et al 1976b). The 
heterogeneity o f H U S I - I preparations seems to be due part ly to proteolyt ic 
degradation in seminal plasma but also to a l l e lomorphism. This 
po l ymorph i sm complicates bo th the pur i f i ca t i on o f H U S I - I to homogeneity 
and the determinat ion o f the amino acid sequence. Basically, the H U S I - I 
molecule consists o f a single polypept ide chain o f about 100 amino acid 
residues which is cross-linked by six disulphide bridges. Pre l iminary results 
give the amino acid sequence shown below for positions 1-24 and 54-99 o f 
H U S I - I f o r m D (cf. Schiessler et al 1978b). I n these sequenced parts o f the 
H U S I - I molecule a s tructura l homology to either a Kazal-type or Kunitz- type 
inh ib i t o r cannot be recognized. This is surpris ing, in that inhib i tors o f similar 
molecular size and inh ib i t o ry properties f ound so far in animals and men are 
bui l t up o f either Kazal- or Kuni tz- type domains (cf. below). 
1 10 













The occurrence o f a new structural inh ib i t o r type, perhaps exclusively in 
humans, wou ld be especially interesting in relat ion to the evolut ion o f prote in 
proteinase inh ib i to rs . I n add i t i on , this wou ld be an indicat ion that H U S I - I 
had developed p r imar i l y for the inh ib i t i on o f granulocytic elastase and 
cathepsin G. This assumption is supported by considering the funct ional 
possibilities o f H U S I - I i n re lat ion to its d i s t r ibut i on w i th in the organism. 
362 Η. F R I T Z E T A I . 
Distribution, site of production and biological function 
Inh ib i tors w i th HUSI - I - l i ke biochemical and/or immunolog ica l properties 
were f ound also in cervical mucus, bronchia l f l u i d , nasal secretion and tears 
(Schiessler 1976, Schiessler et al 1977a, 1978b). Clearly, H U S I - I occurs in 
human mucous f luids open to invading organisms and thus of ten exposed to 
large numbers o f leucocytes dur ing local in f l ammatory processes. The 
concentrat ion o f H U S I - I in these mucous f luids is normal l y far higher (up to 
10 times) than the levels o f the transudated plasma inh ib i tors απ A and απ A C . 
Whereas the IT I -der ived acid-stable inh ib i t o r ITI30000 (cf. above) was also 
f ound in bronchia l fluid (K. Hochstrasser, personal communica t i on 1979), 
aiM is not usually present in human mucous secretions (Table 4). The major 
difference between H U S I - I and the transudated plasma inh ib i tors concerns its 
site o f p roduc t i on : H U S I - I is synthesized locally by the epithel ial cells o f the 
corresponding organs and is thus direct ly secreted in to the mucous fluids 
(Schiessler et al 1978b, Tegner & Ohlsson 1977, Schil l et al 1978). 
F r om the local p roduc t i on , the relatively h igh level in mucous f luids, and 
the inh ib i t o ry spectrum o f H U S I - I (cf. Table 5), i t seems very l ike ly to us that 
H U S I - I has an impor tant defensive func t ion . I t presumably protects soluble 
proteins (such as immunog lobul ins ) and the mucous membranes against 
degradation by leucocytic proteinases l iberated dur ing local in f l ammat i on and 
thus helps the organism to prevent the in f l ammatory response f r o m 
intensi fy ing. Complexes o f H U S I - I w i t h leucocytic and/or bacter ial 
proteinases could indeed be demonstrated i n mucous fluids du r ing 
T A B L E 4 
Inhibitors in human mucous secretions 
Inhibitor Mol. wt. 
(approx.) 
Inhibition of leucocytic: 
Elastase Cathepsin G Neutral proteinase0 
Of plasma origin 
α ιΑΤ 50 000 + + ( + ) + 
onAC 70 000 - + -
I T I 30 000 30 000 - - ? 
( a 2 M ) b 725 000 + + + + + 
Locally produced 
HUSI- I 11 000 + + + — 
+ + , very strong; + , strong; ( + ), weak; - , no inhibit ion. 
aFormerly collagenase (Ohlsson 1980). 
b Only occasionally found during severe inflammation. 
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T A B L E 5 
Acid-stable inhibitors of granulocytic elastase and cathepsin G from various sources. For 
literature references see text 
Inhibition of: 
Inhibitor Source Mol. wt. 
(approx.) Elastase0 Cathepsin G° Chymo­
trypsin0 
Trypsin0 
HUSI-I Human mucous 11 000 + + + + + + + 
secretions 
DSI Dog submandibular 13 000 + + + + + + + 
glands 
A A Soybeans 8000 + + + + + 4- + 
LB I Lima beans 9000 + + + + + + + 
Elastatinal Actinomycetes 500 ( + ) c - - -
Elasnin Streptomyces 400 + d ( + ) ( + ) 
Chymostatin Actinomycetes 600 (- ) + + -
Aprotinin Bovine organs 6500 ( + ) ( + ) + + + 
0 not detected; + + , very strong; + , strong; ( + ), weak; ( - ) , very weak; - , no inhibit ion. 
a Human. bBovine. c Pancreatic: + dPancreatic:(+ ) 
i n f l ammat i on ; even free proteolyt ic act iv i ty may appear when the inh ib i to rs 
are to ta l ly consumed (Schiessler et al 1978b, Ohlsson 1978, K r u m m e et a l 
1977). Clearly, H U S I - I is a funct iona l substitute for α-2-niacroglobulin, 
normal ly inaccessible to mucous fluids. Because o f the l imi ted amount o f 
H U S I - I available f r o m natura l sources — i t has so far been f ound only i n 
humans — we cannot envisage its therapeutic use for some time yet. 
INHIBITORS FROM OTHER SOURCES AS POTENTIAL THERAPEUT iC AGENTS 
Inhib i tors o f granulocyt ic elastase and/or cathepsin G were f ound in 
various natura l sources; some o f them are listed in Table 5. 
inhibitor from dog submandibular glands 
The dog submandibular inh ib i t o r (DSI ) is present in these glands in 
exceptionally high concentrat ion. I t is a secretory prote in consisting o f a 
single polypeptide chain cross-l inked by six disulphide bridges (Fr i tz et al 
1971). The D S I molecule is composed o f two independent inh ib i t o ry active 
domains (Fig. 5) bo th o f which are structural ly homologous to the so-called 
Kazal-type inh ib i tors (Hochstrasser et al 1975) — the pancreatic secretory 
tryps in inh ib i t o r (PSTI ) , the seminal acrosin inh ib i t o r (Tschesche et al 1976) 
and the ovomucoids and ovo inh ib i tors f r o m egg white (Laskowski Jr et al 
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F I G . 5. Covalent structure of the double-headed inhibitor DSI from dog submandibular glands. 
Domain I contains the trypsin-reactive site (Arg-Leu), domain I I the elastase- or chymotrypsin-
reactive centre (Met-Asp). 
1978). The Ν-terminal domain o f D S I contains the trypsin-directed reactive 
site (Arg-Leu) whereas the chymotryps in- or elastase-reactive centre (Met-
Asp) is located in the C-terminal doma in . This structure implies that ternary 
complexes (e.g. a t ryps in-DSI -e las tase complex) may be f o rmed . 
The double-headed DSI molecule probably developed f r om a Kazal-type 
domain (as represented for example by the single-headed PSTI ) by gene 
dupl icat ion and several suitable mutat ions . The dr i v ing force for the 
expansion o f the inh ib i t i on spectrum could have been the need for the 
f o rmat ion o f enzymes w i t h new biological funct ions in the course o f 
evo lut ion . I n this respect it is remarkable that the DSI seems to be especially 
adapted to the food requirements o f canines, as it also inh ib i ts pronase, 
Aspergillus oryzae proteinase and subt i l is in very effectively (Fr i tz et al 1971). 
I n contrast to D S I , H U S I - I does not inh ib i t bacterial and m o u l d proteinases. 
Inhibitors from soybeans and lima beans 
Other inh ib i tors which interact strongly w i th human granulocyt ic elastase 
and cathepsin G are inhib i tors A A f r om soybeans and L B I f r o m l ima beans 
(Schiessler et al 1977b). These inhib i tors are structural ly homologous to each 
other. They consist o f two domains w i th independent reactive sites against 
t ryps in and chymotryps in or elastase (Fig. 6), so that ternary complexes may 
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F I G . 6. Covalent structure of inhibitor AA (Bowman-Birk inhibitor) from soybeans. The trypsin-
reactive site (Lys-Ser) is located in the left loop, the elastase- or chymotrypsin-reactive centre 
(Leu-Ser) in the right loop. 
be f o rmed ( Ikenaka et al 1974). Bo th are readily available in amounts 
suff ic ient for therapeutic studies. However , because agglutinins are present in 
the p lant extracts, they have to be thorough ly pur i f i ed . 
A pro tin in 
The basic t ryps in-ka i l ikre in inh ib i t o r f r om bovine organs, ap ro t in in , used 
as an a f f in i t y adsorbent for the pur i f i ca t ion o f granulocyt ic elastase and 
cathepsin G (Baugh & Travis 1976, Travis et al 1978), turned out to be an 
inh ib i t o r o f these enzymes, too , but w i th relatively low a f f in i ty (Lestienne & 
Bieth 1978, Starkey 1977). Whether inh ib i t i on o f the granulocyt ic proteinases 
plays a role in its therapeutic effectiveness, which is generally assumed to be 
due to the inh ib i t i on o f p lasmin and/or plasma ka l l i k r e in , has st i l l to be 
investigated. 
Microbial peptides 
Recently inhib i tors w i th more restricted specificity and considerably lower 
molecular weight but weaker a f f in i t y to the granulocyt ic proteinases have 
been isolated f r om bacteria (Table 5) (Umezawa 1976, Feinstein 1978, Ohno et 
al 1978). They are potent ia l candidates for studies designed to clari fy the 
pathophysio log ica l role o f ind iv idua l granulocyt ic proteinases in severe 
i n f l ammato r y processes. 
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Inhibitors from the leech Hirudo medicinalis 
Prote in proteinase inh ib i tors isolated so far f r o m extracts o f the leech 
Hirudo medicinalis are listed in Table 6. Hirudin, the thrombin-speci f ic 
inh ib i t o r , turned out to be the effective pr inc ip le o f the leech, widely used 
former ly in medical therapy for ' b l ood d i l u t i o n ' . The biochemical , 
pharmacological and c lo t t ing - inh ib i to ry properties o f h i r u d i n have been 
studied in detail (Ma rkward t 1963, Badgy et al 1976); its amino acid sequence 
has been elucidated recently (Petersen et al 1976). I n our op in i on h i rud in is a 
most promis ing candidate for therapeutic app l i cat ion i n consumpt ion 
coagulopathy, especially i n acquired or hereditary A T I I I deficiency. 
T A B L E 6 
Proteinase inhibitors of the leech Hirudo medicinalis (for further details see text) 
Inhibitor Mol. wt. 
(approx.) 
Inhibition of: 




Hirudin 7000 - _ - + + -
Bdellin A 6000 + + + + + - -
Bdellin Β 4000 + + + + + - -
Eglin 8100 ( + ) - + + + + 
+ + , very strong; + , strong; ( + ), weak; - , no inhibit ion. 
aBovine. bPorcine, human. cBoar, human. dBovine, human. e Human (elastase and cathepsin G). 
The eglins. In the course o f isolat ion o f the bdellins f r om H. medicinalis 
(these are strong inhib i tors o f p lasmin or sperm acrosin, cf. Table 6) an 
ant ichymotryps in act iv i ty was separated. A more detailed investigation 
revealed that this was due to inh ib i tors o f another type, the eglins (Seemüller 
et al 1977). They turned out to be especially strong inhib i tors o f human 
granulocyt ic elastase and cathepsin G, w i th K\ values o f the corresponding 
complexes close to 1.5 χ 1 0 " 1 0 mol/1 (elastase) or 2.5 χ 10" 1 0 mol/1 
(cathepsin G ). In add i t i on , subti l is in is also strongly inhib i ted by the eglins 
(K\ approx. 1.2 χ 10" 1 0 mol/1). The eglins are a mix ture o f iso inhibi tors w i th 
s imi lar biochemical and inh ib i to ry properties. 
The amino acid sequence shown below was elucidated very recently for 
eglin c. 
I t is most surprising that the eglins are extremely resistant to denaturat ion 
and proteolyt ic degradation, despite the lack o f any disulphide bond which 




Pro-Glu-Va l -Va l -G ly -Lys-Thr-Va l -Asp-Gln-
30 






Arg-Va l -Arg-Va l -Phe-Tyr-Asn-Pro-Gly-Thr-
70 
Asn-Val -Va l -Asn-His-Va l -Pro-His-Va l -Gly 
could stabilize the structure o f the molecule. This new structural type o f 
prote in proteinase inh ib i t o r seems to be especially suitable, therefore, for 
therapeutic use in both local and generalized in f l ammat i on . I n this respect it 
is remarkable that the an t i - in f l ammatory ( 'anti-phlogist ic ' ) effect o f leech 
extracts has long been k n o w n ; it could be at least part ly due to the 
ant iproteo lyt ic effect o f the eglins. 
It is evident f r om these results that quite dif ferent structural approaches (cf. 
H U S I - I , i nh ib i t o r A A and eglin c) may lead to a reactive site con fo rmat i on 
which fits perfectly in to the active site o f the same enzyme (e.g. o f 
granulocyt ic elastase). 
INHIBITOR THERAPY IN EXPERIMENTAL ENDOTOXAEMIA 
The endotoxaemia model 
Experimental procedure, Endotoxaemia was induced in six anaesthetized 
dogs by cont inuous in fus ion o f Escherichia coli endotox in , 2 mg/kg body 
weight, in to the in fer ior vena cava over a period o f two hours. The six con t ro l 
dogs were subjected to the same procedure except that isotonic saline was 
infused instead o f the endotox in so lut ion . The data moni to red or collected 
just before endotox in (or isotonic saline) appl icat ion served as 100% values 
for each parameter. A l l values obtained dur ing the 14-hour experiment were 
expressed as percentages o f these start ing values. Further clearly defined 
experimental condit ions a l l ow ing a statistical treatment o f the results by the 
three factor ia l classif ication o f variance w i l l be published elsewhere ( M . 
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Jochum, J . Wi t t e , H . Schiessler, G. Ruckdeschel & H . Fr i t z , in preparat ion) . 
T o determine the plasma levels o f c lo t t ing and f ibr inolysis factors we used 
amido ly t ic assays w i th chromogenic substrates: T o s G l y P r o A r g N H N p 
(Boehringer) for p r o t h r o m b i n , D - P h e P i p A r g N H N p (S-2238 K A B I ) for A T 
I I I , and D - V a l L e u L y s N H N p (S-2251 K A B I ) for plasminogen and a 2 P I . The 
biological act iv i ty o f factor X I I I was assayed according to the procedure 
' Fak to r X I I I Schnelltest' f r om Behringwerke Marburg/Germany , whi le 
complement factor C3 was quant i f ied by the radia l immunod i f f u s i on 
technique. 
Haematological data. I n contrast to the contro l group the endotox in-
treated dogs showed a rap id and substantial decrease in c i rculat ing platelets 
and leucocytes (Figs. 7 and 8). I n add i t i on , a strong leucocytosis developed in 
the endotoxin group, producing leucocyte counts far higher than before 
endotox in adminis t ra t ion (Fig. 8). 
Plasma factors. Compared to the cont ro l group the levels o f the selected 
plasma factors decreased substantially in the endotoxin-treated dogs up to six 
hours ( A T I I I , c ^ P I , p r o t h r o m b i n , complement C3) or 14 hours 

















F I G . 7. Behaviour pattern of circulating platelets in experimental endotoxaemia. The curves 
represent mean values χ of the control (full line, η = 6) and endotoxin groups (dashed line, η = 
6); the standard deviations, ± SEM, are indicated for each test point. Ordinate, number o f 
platelets/μΐ plasma. Abscissa, observation period. The endotoxin infusion period is indicated as 
a thick line on the abscissa. 
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F I G . 8. Behaviour pattern of circulating leucocytes in experimental endotoxaemia. The curves 
represent mean values χ of the control (full line, η = 6) and endotoxin groups (dashed line, η -
6); the standard deviations, ± SEM, are indicated for each test point. Ordinate, number of 
leucocytes/μΐ plasma. Abscissa, observation period. The endotoxin infusion period is indicated 
as a thick line on the abscissa. 
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F I G . 9. Plasma levels of selected plasma factors during experimental endotoxaemia (left) and 
under inhibitor medication (right). The curves represent mean values χ of the control groups A (n 
= 6), the endotoxaemia group Β (η = 6) and the inhibitor-medicated endotoxaemia group (right 
panel, η = 4); standard deviations are given elsewhere (Witte 1979). Ordinate, the percentage of 
the starting level (cf. text). Abscissa, experimental period (the endotoxin infusion period is 
indicated by the thick line). For further details see text. 
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also true for the f ibr inogen concentrat ion (80% o f the start ing value at the end 
o f the experiment, not shown in the f igure) . The paral le l decrease i n the 
physiological antagonists p r o t h r o m b i n / A T I I I and plasminogen/a2PI is 
especially remarkable. 
Establishment of the model. The statistical evaluation revealed that the 
differences i n the levels o f the plasma factors and b lood cell counts were 
statistically signif icant for the cont ro l and endotoxaemia g roup 
(P <0.05/0.001) , the various test times (P <0.04/0.001) , and the t ime course 
(P <0.05/0.001) . This result clearly shows the va l id i ty o f this experimental 
system as a model for endotoxaemia. I n fact, the substantial alterations 
observed in b lood cell counts and the levels o f the selected plasma proteins are 
characteristic o f endotoxin- induced D I C (McCabe 1973, Garner et al 1974, 
Urbaschek et al 1975, Müller-Berghaus et al 1976, Aasen et al 1978a, 1978b, 
1980). 
influence of inhibitor medication 
Experimental procedure. I n a f irst approach the elastase-cathepsin G 
inh ib i t o r A A f r om soybeans (cf. Table 5), described or ig inal ly by B o w m a n 
and B i rk (B i rk 1976), was applied in the endotoxaemia model in the dog. The 
inh ib i t o r was isolated f r om a commercia l ly available soybean extract ( ' t ryps in 
inh ib i t o r f r om soybeans' f r om Serva, Heidelberg, no. 37 340) by repeated gel 
f i l t r a t i on chromatography on Sephadex G-75 in 2 % acetic acid so lut ion ( H . 
Schiessler, personal communica t ion 1978). I n the inh ib i t o r medicat ion g roup 
( four dogs) infusions o f endotox in (cf. above) and inh ib i t o r were started 
simultaneously but the inh ib i to r infusion was cont inued over the to ta l 
experimental per iod (14 h) . Each o f the four animals received 3 -8 mg/kg 
body weight o f the pur i f i ed inh ib i to r w i th a specific trypsin inh ib i to ry act iv i ty 
(substrate B z A r g N H N p ) close to 3.2 I U / m g . Further experimental details w i l l 
be published elsewhere ( M . Jochum, J . Wi t t e , Η. Schiessler, G. Ruckdeschel 
& H . Fr i t z , in preparat ion) . 
Results and outlook. The inh ib i to r medicat ion influenced the behaviour 
pattern o f neither the c irculat ing platelets nor the leucocytes when compared 
to the endotox in group. However, the endotoxin- induced decrease in plasma 
levels o f the selected factors was signi f icantly (P <0 .05/0 .01 , Student Mest ) 
reduced by inh ib i t o r treatment (Fig. 9) ; even the lowest dosage o f i nh ib i t o r 
used (3 mg/kg body weight) was effective. As may be deduced f r o m the 
i nh ib i t i on spectrum o f inh ib i t o r A A , degradation o f the plasma factors i n the 
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course o f endotoxaemia is due chief ly to unspecific proteolysis rather than to 
act ivat ion o f the b l ood systems by system-specific proteinases, though 
quant i ta t i on o f the degree o f consumpt ion due to unspecific proteolysis is not 
yet feasible. 
The results o f bo th the c l inical and experimental study indicate clearly that 
in generalized in f l ammato ry processes such as septicaemia or septic shock the 
regulatory inh ib i t o r system o f the organism may be overstressed. As shown 
for the first t ime in the endotoxaemia t r i a l , a suitable inh ib i t o r can 
signi f icantly prevent unspecific degradation o f plasma factors by leucocytic 
(and other?) proteinases and thus help the natural defence mechanisms to 
ma in ta in the physiological balance. I n view o f the key funct ion o f caM in the 
rap id e l iminat ion o f proteinases f r om the c i rculat ion, protect ion against early 
ouM consumpt ion could be the under ly ing explanation for the effectiveness o f 
such an exogenous inh ib i t o r . 
Just as impor t an t , i t seems to us, is to minimize hypercoagulabi l i ty and 
hyperf ibr inolys is or D I C induced simultaneously by system-specific 
proteinases. For this purpose ap ro t i n in , a strong plasmin inh ib i t o r already 
used in medical therapy, and the thrombin-speci f ic inh ib i to r h i rud in (cf. 
Table 6) are potent ia l candidates, the latter especially i f A T I I I is consumed to 
such an extent that heparin medicat ion is o f reduced effectiveness. As the 
systemic appl icat ion o f suitable elastase-cathepsin G inhib i tors and h i r u d i n in 
humans is not possible u n t i l tox ico logical , pharmacological and cl inical tr ia ls 
have been sucessfully made, subst i tut ion w i th A T I I I (Schramm 1977, 
Schramm et al 1978) and aiM concentrates is the method o f choice at present. 
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